(Q43825051)

27 November 2017

title

The multiple sclerosis risk gene IL22RA2 contributes to a more severe murine autoimmune neuroinflammation (English)

1 reference

27 November 2017

0 references

0 references

H Laaksonen

1

0 references

Roham Parsa

object named as

R Parsa

4

0 references

Tommy Olsson

7

object named as

T Olsson

1 reference

27 November 2017

A O Guerreiro-Cacais

2

1 reference

27 November 2017

M Z Adzemovic

3

1 reference

27 November 2017

M Zeitelhofer

5

1 reference

27 November 2017

M Jagodic

6

1 reference

27 November 2017

publication date

10 July 2014

1 reference

27 November 2017

1 reference

27 November 2017

volume

15

1 reference

27 November 2017

issue

7

1 reference

27 November 2017

page(s)

457-465

1 reference

Estimation of the cost of MS in Europe: extrapolations from a multinational cost study

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-22RA2 Associates with Multiple Sclerosis and Macrophage Effector Mechanisms in Experimental Neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Structure of IL-22 bound to its high-affinity IL-22R1 chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-22 increases the innate immunity of tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2014.36

IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25008863

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25008863

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/GENE.2014.36

1 reference

27 November 2017

1 reference